Table 2. In vivo efficacy of anetumab ravtansine as a monotherapy in a panel of ovarian cancer cell line- and patient-derived xenograft models.
| Xenograft model | CDX/PDX | Ovarian cancer subtype | T/C (2.5 mg/kg) | IHC score (0–3) | H score (0–300) |
|---|---|---|---|---|---|
| ST081 | PDX | High-grade serous ovarian cancer | 0a,* | 3 | 150 |
| ST103 | PDX | High-grade serous ovarian cancer | 0a,* | 3 | 210 |
| ST270 | PDX | High-grade serous ovarian cancer | 0.04a,* | 3 | 185 |
| OVCAR-3 | CDX | High-grade serous ovarian cancer | 0.17* | 3 | 180 |
| ST467 | PDX | Serous papillary carcinoma | 0.25 | 2 | 180 |
| ST409 | PDX | High-grade serous ovarian cancer | 0.36* | 3 | 230 |
| OVCAR-8 | CDX | High-grade serous ovarian cancer | 0.58* | 2 | 175 |
| ST206B | PDX | Serous papillary carcinoma | 0.73 | 2 | 160 |
| Ov6645 | PDX | Malignant mixed Müllerian carcinosarcoma | 1.83 | 0 | 0 |
| ST2054 | PDX | High-grade serous ovarian cancer | 1.37 | 1 | 50 |
aAnetumab ravtansine administered at 15 mg/kg, Q2W
*Significantly different in comparison to vehicle control (p < 0.05, n = 3–10)
CDX, cell line-derived xenograft; IHC, immunohistochemistry; PDX, patient-derived xenograft; T/C, treatment/control